Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F19%3A00012445" target="_blank" >RIV/00023736:_____/19:00012445 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10378476 RIV/00216208:11120/19:43917063 RIV/00216208:11130/19:10378476 RIV/00216208:11150/19:10378476 and 6 more
Result on the web
<a href="https://doi.org/10.1080/10428194.2018.1508672" target="_blank" >https://doi.org/10.1080/10428194.2018.1508672</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/10428194.2018.1508672" target="_blank" >10.1080/10428194.2018.1508672</a>
Alternative languages
Result language
angličtina
Original language name
Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry
Original language description
We analyzed 495 MCL patients from the Czech Lymphoma Study Group data registry. With the median follow-up of 4.4 years, 51.7% patients progressed or relapsed and 34.1% died. Five-year overall survival reached 65.3% and five-year progression free survival 44.1% of the patients. Maintenance rituximab (MR) after first line therapy improved overall and progression free survival compared to the patients under observation only (both p <.001). Autologous stem cell transplant reduced the risk of MR failure by 69% (p <.001).
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV16-31092A" target="_blank" >NV16-31092A: Population of Elderly Patients with Non-Hodgkin´s Lymphomas – the Analysis of Factors Affecting the Management and Outcome</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia & lymphoma
ISSN
1042-8194
e-ISSN
—
Volume of the periodical
60
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
748-755
UT code for WoS article
000463704200024
EID of the result in the Scopus database
2-s2.0-85053256091